VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Wu on Possible Combinations With TAS-102 in CRC

Jennifer Wu, MD
Published: Wednesday, Dec 23, 2015



Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer (CRC).

TAS-102 is currently being investigated in combination with oxaliplatin in preclinical models, Wu says. Data reported earlier in 2015 have shown that clinical activity was demonstrated in refractory patients with CRC when TAS-102 was combined with bevacizumab.

Looking ahead, Wu says TAS-102 will be a part of novel combinations in CRC, possibly even with stem cell inhibitors.



Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer (CRC).

TAS-102 is currently being investigated in combination with oxaliplatin in preclinical models, Wu says. Data reported earlier in 2015 have shown that clinical activity was demonstrated in refractory patients with CRC when TAS-102 was combined with bevacizumab.

Looking ahead, Wu says TAS-102 will be a part of novel combinations in CRC, possibly even with stem cell inhibitors.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x